<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Biglycan has been considered a good candidate for <z:e sem="disease" ids="C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular disease</z:e> based on direct interactions with collagen VI and alpha-dystroglycan, both of which are linked with <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (CMD) </plain></SENT>
<SENT sid="1" pm="."><plain>We screened 83 patients with CMD and other <z:e sem="disease" ids="C0852419,C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular disorders</z:e> and six controls for mutations and variations in the biglycan sequence </plain></SENT>
<SENT sid="2" pm="."><plain>We identified a number of novel sequence variations </plain></SENT>
<SENT sid="3" pm="."><plain>After family analysis and control screening we found that none of these polymorphisms were disease-causing mutations </plain></SENT>
<SENT sid="4" pm="."><plain>Thus mutations in biglycan are not a common cause of <z:e sem="disease" ids="C0852419,C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular disorders</z:e> in our cohort </plain></SENT>
</text></document>